The Efficacy of Infliximab Monotherapy versus Infliximab-Azathioprine Sequential Treatment in Crohn’s Disease: Experience from a Tertiary Medical Center in China

Abstract EN

Objective.

To evaluate the efficacy of infliximab (IFX) monotherapy versus infliximab-azathioprine sequential treatment in Crohn’s disease (CD) patients.

Methods.

Patients newly diagnosed with CD using IFX as induction therapy were enrolled.

After 6 times of IFX infusions, they were divided into IFX monotherapy group and IFX-AZA sequential therapy group.

Clinical remission rates were assessed at weeks 57, 84, 111, and 138 while endoscopic remission rates were assessed at weeks 84 and 138 to evaluate the efficacy of these two groups.

Results.

A total of seventy-nine patients had accomplished 138-week follow-up.

At weeks 84 and 138, the deep remission rate (18/22 and 17/22) of IFX monotherapy group was significantly higher compared to IFX-AZA sequential therapy group (26/57 and 21/57) (P=0.004 and 0.001, resp.).

Similar findings were found in complete endoscopic remission rate.

The clinical remission rates of IFX monotherapy group were similar to that of IFX-AZA sequential therapy group (P>0.05).

At weeks 84 and 138, the endoscopic remission rate and the endoscopic improvement rate between these two groups displayed no significant difference (P>0.05).

Conclusion.

IFX monotherapy provides higher deep remission rate compared with IFX-AZA sequential therapy in two-year maintenance therapy.

For patients who could not receive prolonged IFX therapy, IFX-AZA sequential therapy is acceptable, though long-term efficacy remains to be seen.